

REVIEW

Open Access

Escherichia coli type III secretion system 2: a new kind of T3SS?

Mingxu Zhou^{1,2}, Zhiyan Guo^{1,2}, Qiangde Duan^{1,3}, Philip R Hardwidge⁴ and Guoqiang Zhu^{1,2*}

Abstract

Type III secretion systems (T3SSs) are employed by Gram-negative bacteria to deliver effector proteins into the cytoplasm of infected host cells. Enteropathogenic *Escherichia coli* use a T3SS to deliver effector proteins that result in the creation of the attaching and effacing lesions. The genome sequence of the *Escherichia coli* pathotype O157:H7 revealed the existence of a gene cluster encoding components of a second type III secretion system, the *E. coli* type III secretion system 2 (ETT2). Researchers have revealed that, although ETT2 may not be a functional secretion system in most (or all) strains, it still plays an important role in bacterial virulence. This article summarizes current knowledge regarding the *E. coli* ETT2, including its genetic characteristics, prevalence, function, association with virulence, and prospects for future work.

Table of contents

1. Introduction
2. Genetic characteristics and differentiation of ETT2
3. Prevalence and distribution of ETT2
4. Putative functions of the ETT2
 - 4.1 ETT2 encodes a functional secretion system?
 - 4.2 ETT2 regulates bacterial virulence
 - 4.3 Association of ETT2 with other virulence factors
5. Conclusions
6. Competing interests
7. Authors' contributions
8. Acknowledgements
9. References

1. Introduction

Many pathogenic Gram-negative bacteria utilize type III secretion systems (T3SSs) to subvert eukaryotic signaling pathways by injecting virulence proteins into the host cell cytoplasm [1-5]. Intracellular pathogens, such as *Salmonella*, *Shigella*, and *Chlamydia*, use T3SS for attachment to and/or invasion of host cells [6-8]. *Yersinia enterocolitica* and *Yersinia pseudotuberculosis* induce

macrophage apoptosis and subvert host innate immunity by injecting effectors through the T3SS [9-11]. Enteropathogenic *E. coli* (EPEC) and enterohemorrhagic *E. coli* (EHEC) use the T3SS to deliver effector proteins that result in the creation of the attaching and effacing (A/E) lesions [12,13]. *Salmonella* utilize multiple type III secretion systems, with the first, *Salmonella* pathogenicity islands 1 (SPI-1) T3SS, playing a role in invasion into host cells, while the second, SPI-2 T3SS, is important for intracellular survival [14]. The complete genome sequencing of two EHEC O157:H7 strains, EDL933 and Sakai, revealed the presence of a gene cluster predicted to encode an additional T3SS. This T3SS was designated as the *E. coli* type III secretion system 2 (ETT2), to distinguish it from the locus of enterocyte effacement (LEE) - encoded T3SS, which is now called ETT1 [15,16].

EHEC and other Shiga-like toxin-producing *E. coli* (STEC), including the O157:H7 serotype, are responsible for diseases in humans and animals whose clinical spectrum includes diarrhea, hemorrhagic colitis, and hemolytic uremic syndrome (HUS) [17-20]. There are no proven effective treatments, and administering antibiotics is often contraindicated because they may enhance the progression of enteritis to HUS [21]. While the function of the EHEC ETT1 has been well characterized [22-25], the function of ETT2 and its role in virulence is less clear.

* Correspondence: yzqzhu@yzu.edu.cn

¹College of Veterinary Medicine, Yangzhou University, Yangzhou 225009, China

²Jiangsu Co-Innovation Center for Important Animal Infectious Diseases and Zoonoses, Yangzhou 225009, China

Full list of author information is available at the end of the article

2. Genetic characteristics and differentiation of ETT2

The genes required for ETT1 function, including the T3SS apparatus and the secreted proteins, are encoded on the LEE in EPEC and EHEC. This virulence locus is about 35.4-kb in size and contains 41 open reading frames (ORFs) [24-26]. Up to 32 other non-LEE-encoded effector proteins can also be delivered into host cells by the ETT1 to subvert eukaryotic cell biology [27]. The ETT2 is approximately 29.9-kb in size and is adjacent to the tRNA locus *glyU* on the bacterial chromosome (Figure 1). The ETT2 gene cluster includes at least 35 ORFs, from ECs3703 to ECs3737 in the Sakai strain (GenBank: NC_002695; Table 1). The G + C content of the ETT2 sequence is lower (36.9%) than that of the *E. coli* chromosome (50.8%), suggesting that the ETT2 gene cluster was a pathogenicity island inserted into EHEC O157:H7 strains [28,29].

It has been shown that the ETT2 gene cluster exists in whole or in part in the majority of *E. coli* strains, regardless of their pathogenicity, but with significant variability [29-31]. Sequence alignment analysis revealed that the ETT2 with all 35 ORFs in the Sakai strain also contains some pseudogenes, while EAEC 042 not (Figure 1, [31]). Cheng divided ETT2 variants into 11 isoforms (designated as type A to type K), with type A representing the complete ETT2 island with 35 ORFs [32].

3. Prevalence and distribution of ETT2

The ETT2 gene cluster is primarily associated with STEC strains. Hartleib et al. detected the presence of ETT2 locus in 245 strains of *E. coli*, in 25 strains of *Salmonella enterica*, and in 10 other bacteria, using both PCR and Southern blotting. The ETT2 was distributed ubiquitously among intestinal *E. coli* strains, but not in extra-intestinal (including serotypes O2:H7, O6:H12, O18:H7) or non-pathogenic (including serotypes O5, O74) *E. coli* strains or in other enteric bacteria such as *Salmonella*, *Yersinia*, and *Shigella* [28]. Serotype O55:H7 strains were shown to be the most recent precursors of the virulent O157:H7 EHEC strains

[33]. BLAST Genome on NCBI revealed O55:H7 EPEC strains share 49% fragment of the intact ETT2 cluster, losing almost all genes from ECs3711 to ECs3731 (Table 1). Genome analysis also showed that, all whole-genome sequenced EPEC strains (except serotype O127:H6) and STEC (including serotypes both O157 and non-O157) strains carry the ETT2 gene cluster.

ETT2 is prevalent in a majority of characterized human diarrheagenic *E. coli* isolates (54/83; 65%), and all STEC strains tested (except serotype O177) contain the ETT2 gene cluster [34]. However, ETT2 prevalence in uropathogenic *E. coli* (UPEC) strains is low [35].

In animal originated *E. coli* strains, ETT2 is also common. Cheng et al. isolated 92 pathogenic *E. coli* strains from weaned piglets with edema and/or diarrhea and 76 pathogenic *E. coli* strains from dairy cows with clinical or sub-clinical mastitis and detected the ETT2 ORFs by PCR. Most isolates (85.9%) from piglets contained an intact or partial ETT2 gene cluster, significantly higher than those isolated from cows (47.4%) [32]. Prager also identified ETT2 loci in 117 STEC strains originating from piglets suffering from edema disease or colibacillosis [30].

4. Putative functions of the ETT2

4.1 ETT2 encodes a functional secretion system?

The T3SSs are comprised of a basal body that spans the cell membranes and a needle-like complex that extends from the outer membrane, through which effectors are secreted. The basal body consists of an inner ring, an outer ring, and a neck that spans the periplasm. A functional T3SS requires additional elements, including a cytosolic regulatory complex linked to the basal body, an inner rod that constitutes the base of the needle, and a translocon protein complex that forms a pore in the host membrane [36].

The ETT2 gene cluster was originally regarded as a SPI-1-like island, of which 19 ORFs are highly homologous with the SPI-1 T3SS of *Salmonella enterica* serovar Typhmurium [37,38]. However, some significant differences exist between the *E. coli* ETT2 and SPI-1 T3SS:




Figure 1 Structure of ETT2 gene cluster in strain EHEC Sakai and EAEC 042. The ETT2 gene cluster includes 35 ORFs (ECs3703 – ECs3737) and is adjacent to the tRNA locus *glyU* on the bacterial chromosome. Frame in yellow indicates gene encoding a chaperone, red indicates gene coding for a transcriptional regulator, blue indicates gene encoding other pathogenicity island (PAI) gene, stripe indicated gene is a pseudogene.

Table 1 Homologs and putative functions of ETT2 ORFs

Gene in Sakai strain	Length (bp)	Homologs*	Putative function
ECs3703	693	<i>yqeH</i>	
ECs3704	810	<i>yqeI</i>	Sensory transducer
ECs3705	480	<i>yqeJ</i>	
ECs3706	438	<i>yqeK</i>	
ECs3707	492	<i>yqeF</i>	
ECs3708	492	<i>ygeG,sicA</i>	Chaperone
ECs3709	1377	<i>ygeH</i>	Transcriptional regulator
ECs3710	219	B2853	
ECs3711	402	B2854, <i>iagB</i>	
ECs3712	633	<i>ygeK/B2856, ssrB</i>	Regulator
ECs3713	432	B2857	
ECs3714	261	B2858, <i>orgB</i>	
ECs3715	582	B2859, <i>orgA</i>	
ECs3716/ <i>eprK</i>	735	<i>prgK</i>	Lipoprotein precursor
ECs3717/ <i>eprJ</i>	333	<i>prgJ, mxil</i>	
ECs3718/ <i>eprI</i>	240	<i>prgI, mxIH</i>	
ECs3719/ <i>eprH</i>	735	<i>prgH, mxIG</i>	
ECs3720/ <i>etrA</i>	501	<i>ntrC</i>	Transcriptional regulator
ECs3721/ <i>epaS</i>	1122	<i>spaS</i>	Surface presentation of antigens protein
ECs3722/ <i>epaR2</i>	237	<i>spaR</i>	
ECs3723/ <i>epaR1</i>	468		
ECs3724/ <i>epaQ</i>	261	<i>spaQ</i>	
ECs3725/ <i>epaP</i>	666	<i>spaP</i>	Surface presentation of antigens protein
ECs3726/ <i>epaO</i>	987	<i>spaO</i>	Surface presentation of antigens protein
ECs3727/ <i>eivJ</i>	618	<i>spaN/invJ</i>	
ECs3728	234		
ECs3729/ <i>eivI</i>	336	<i>spaM/invI</i>	
ECs3730/ <i>eivC</i>	1320	<i>spaI/invC</i>	Invasion protein
ECs3731/ <i>eivA</i>	2061	<i>invA</i>	
ECs3732/ <i>eivE</i>	1146	<i>invE</i>	Invasion protein
ECs3733/ <i>eivG</i>	1704	<i>invG</i>	
ECs3734/ <i>eivF</i>	750	<i>invF</i>	Transcriptional regulator
ECs3735	180	<i>ycdX</i>	Inner membrane protein
ECs3736/ <i>pkgA</i>	1059	B2863	Phosphorylase kinase and glucoamylase
ECs3737	606	B2862	

**yqeHIJK, ygeFGH, ycdX, B2853, B2354, B2356-B2359, B2362, and B2363* are conserved genes in *E. coli* K-12. *orgA, orgB, iagB, prgHIJK, spaOPQRS, invA, invC, invE, invF, invG, invI, and invJ* are *Salmonella enterica* SPI-1 genes. *mxil, mxIG* and *mxIH* are *Shigella flexneri* genes. *ntrC* is from *Herbaspirillum seropedicae*.

(i) *spaR* (encoding the T3SS inner ring) is divided into two ORFs, *epaR1* and *epaR2*, in the ETT2 gene cluster, and (ii) *invB* and *invH* are absent from the ETT2 gene cluster. In the *Salmonella* SPI-1 T3SS, InvB is required for secretion and translocation of SopE and SopE2 and for stabilization of SopE2 in the bacterial cytosol [39]. InvH is necessary for localization of InvG to the outer membrane, but InvH is not a component of the type III secretion apparatus [40]. Several important T3SS structural genes, including *prgH* (encoding the inner ring) and *sipABCD* (encoding the needle tip and translocon), are disrupted by frameshifts or are absent [41]. Thus, it appears that this partial ETT2 gene cluster itself does not encode a functional secretion system in EHEC O157 [31].

Nevertheless, even if some necessary genes are missing or nonfunctional in ETT2, it seems possible that genes in ETT1 might complement those gene functions, in order to construct a working apparatus for secretion. Otherwise, *pkgA*, a gene at one end of ETT2 cluster encoding a putative glucoamylase that targets glycogen metabolism within host cell was identified, and speculated to be a ETT2 effector [42]. Another four putative effector genes disrupted by frameshifts in EHEC were found in the EAEC 042 as well, indicating there still has possibility of secretion ability of ETT2 in the future [43].

4.2 ETT2 regulates bacterial virulence

However, the ETT2 still plays a crucial role in virulence. Co-regulation between the T3SSs is important to *Salmonella* biology. Normally, effectors encoded in SPI-1 are translocated specifically by the SPI-1 T3SS and effectors encoded in SPI-2 are translocated specifically by the SPI-2 T3SS. Interestingly, sometimes, the *Salmonella* T3SS translocates certain proteins encoded not only in SPI-1, but also outside the locus [44,45]. SPI-2 T3SS could translocate both effectors encoded in SPI-1 and SPI-2. The ETT2 gene cluster can also regulate genes encoded elsewhere on the chromosome.

Zhang et al. targeted the *ygeH* (ECs3709), *etrA* (ECs3720), and *eivF* (ECs3734) genes of the Sakai 813 strain, and demonstrated the negative effects on gene transcription within the LEE by EtrA and EivF: deletion of *etrA* and *eivF* led to increased secretion of proteins encoded by the LEE and to increased adhesion to human intestinal cells [46].

The degenerate ETT2 gene cluster from *E. coli* O157:H7 can not only regulate the expression of virulence-associated genes encoded elsewhere, but also can affect bacterial virulence. Ideses et al. compared the virulence of WT *E. coli* 789 with ETT2 deletion mutants in 1-day-old chickens and found that the ETT2 mutant was substantially attenuated [47]. Yao et al. deleted either the entire ETT2 gene cluster or only *eivA* (ECs3732) gene in

the meningitis-causing *E. coli* K1 strain EC10 and observed that the ETT2 deletion mutant exhibited both a 50% reduction in invasion and an 80% decrease in intracellular survival in human brain microvascular endothelial cells (HBMECs) as compared with WT EC10 [48], which indicated that ETT2 is necessary in the pathogenic process of *E. coli* strain K1 interacting with host cells. Sheikh et al. also reported that a *hilA* (encoding a *Salmonella enterica* regulator) homolog, *eilA*, coordinately activated both the EivF, EivA and presumably other effectors encoded elsewhere on the genome (adjacent to tRNA locus *selC*), influencing both bacterial adherence to epithelial cells and biofilm formation, which indirectly suggested the role of ETT2 in bacterial virulence [49,50].

4.3 Association of ETT2 with other virulence factors

In the veterinary field, as the ETT2 is primarily associated with EHEC and STEC, it is common to find Stx2e in ETT2 positive strains [32]. In other pathogenic *E. coli* of different O: H serotypes, the ETT2 island is also associated with one or more pathogenicity islands, such as LEE, HPI and LPA [28].

Prager et al. investigated 266 STEC isolates from various human clinical sources and found that different virulence genes were associated with the ETT2. Some genes, including *stx2d* (encoding a Shiga toxin activated by elastase) occur alone or in combinations with ETT2 or LPA, but never with the LEE [51]. It will be important to confirm whether the expression and/or secretion of these virulence factors are affected by the ETT2 island.

5. Conclusions

The ETT2 is prevalent in pathogenic EHEC and STEC strains and is likely important to both human and veterinary medicine. While the exact function of the ETT2 has not been defined clearly, rather than encoding a secretion system, recent work has demonstrated its importance to bacterial adherence and in regulating the expression of other virulence factors, and further study of the ETT2 may help to elucidate details governing bacterial virulence gene regulation. While most serotypes of *E. coli* carry an impaired ETT2 gene cluster, the presence of an intact ETT2 might be used to identify highly-pathogenic EHEC or STEC strains and for molecular fingerprinting of epidemic strains in humans and animals.

6. Competing interests

The authors declare that they have no competing interests.

7. Authors' contributions

MZ and ZG collected the data. MZ reviewed the collections and wrote the manuscript. GZ, PRH and QD gave their comments and helped revising this manuscript. All authors read and approved the final manuscript.

8. Acknowledgements

This study was supported by grants from the Chinese National Science Foundation Grants (No.31270171, No.31072136 and No.30771603), 948 programme from Ministry of Agriculture of the People's Republic of China (grant No. 2011-G24), and the Genetically Modified Organisms Technology Major Project of China (2014ZX08006-001B), a project founded by the Priority Academic Program of Development Jiangsu High Education Institution, Program for Changjiang Scholars and Innovative Research Team In University "PCSIRT" (IRT0978), Program granted for Scientific Innovation Research of College Graduate in Jiangsu province (CXZZ13_0913).

Author details

¹College of Veterinary Medicine, Yangzhou University, Yangzhou 225009, China. ²Jiangsu Co-Innovation Center for Important Animal Infectious Diseases and Zoonoses, Yangzhou 225009, China. ³Agriculture College, Weinan Vocational and Technical College, Weinan 714000, China. ⁴College of Veterinary Medicine, Kansas State University, 66506 Manhattan, KS, USA.

Received: 29 November 2013 Accepted: 7 March 2014

Published: 19 March 2014

9. References

1. Hueck CJ: Type III protein secretion systems in bacterial pathogens of animals and plants. *Microbiol Mol Biol Rev* 1998, **62**:379–433.
2. Kenny B: Mechanism of action of EPEC type III effector molecules. *Int J Med Microbiol* 2002, **291**:469–477.
3. Lee CA: Type III secretion systems: machines to deliver bacterial proteins into eukaryotic cells? *Trends Microbiol* 1997, **5**:148–156.
4. Cornelis GR: *Yersinia* type III secretion: send in the effectors. *J Cell Biol* 2002, **158**:401–408.
5. Bao X, Beatty WL, Fan H: Exploration of chlamydial type III secretion system reconstitution in *Escherichia coli*. *PLoS One* 2012, **7**:e50833.
6. Ménard R, Dehio C, Sansonetti PJ: Bacterial entry into epithelial cells: the paradigm of *Shigella*. *Trends Microbiol* 1996, **4**:220–226.
7. Galan JE: *Salmonella* interactions with host cells: type III secretion at work. *Annu Rev Cell Dev Biol* 2001, **17**:53–86.
8. Fields KA, Mead DJ, Dooley CA, Hackstadt T: *Chlamydia trachomatis* type III secretion: evidence for a functional apparatus during early-cycle development. *Mol Microbiol* 2003, **48**:671–683.
9. Mills SD, Boland A, Sory MP, van der Smissen P, Kerbouch C, Finlay BB, Cornelis GR: *Yersinia enterocolitica* induces apoptosis in macrophages by a process requiring functional type III secretion and translocation mechanisms and involving YopP, presumably acting as an effector protein. *Proc Natl Acad Sci U S A* 1997, **94**:12638–12643.
10. Monack DM, Meccas J, Ghori N, Falkow S: *Yersinia* signals macrophages to undergo apoptosis and YopJ is necessary for this cell death. *Proc Natl Acad Sci U S A* 1997, **94**:10385–10390.
11. Bliska JB, Wang X, Viboud G, Brodsky IE: Modulation of innate immune responses by *Yersinia* type III secretion system translocators and effectors. *Cell Microbiol* 2013, **15**:1622–1631.
12. Celli J, Deng W, Finlay BB: Enteropathogenic *Escherichia coli* (EPEC) attachment to epithelial cells: exploiting the host cell cytoskeleton from the outside. *Cell Microbiol* 2000, **2**:1–9.
13. Jarvis KG, Kaper JB: Secretion of extracellular proteins by enterohemorrhagic *Escherichia coli* via a putative type III secretion system. *Infect Immun* 1996, **64**:4826–4829.
14. Silva-Herzog E, Detweiler CS: *Salmonella enterica* replication in hemophagocytic macrophages requires two type three secretion systems. *Infect Immun* 2010, **78**:3369–3377.
15. Hayashi T, Makino K, Ohnishi M, Kurokawa K, Ishii K, Yokoyama K, Han CG, Ohtsubo E, Nakayama K, Murata T, Tanaka M, Tobe T, Iida T, Takami H, Honda T, Sasakawa C, Ogasawara N, Yasunaga T, Kuhara S, Shiba T, Hattori M, Shinagawa H: Complete genome sequence of enterohemorrhagic *Escherichia coli* O157:H7 and genomic comparison with a laboratory strain K-12. *DNA Res* 2001, **8**:11–22.
16. Perna NT, Plunkett G 3rd, Burland V, Mau B, Glasner JD, Rose DJ, Mayhew GF, Evans PS, Gregor J, Kirkpatrick HA, Pósfai G, Hackett J, Klink S, Boutin A, Shao Y, Miller L, Grotbeck EJ, Davis NW, Lim A, Dimalanta ET, Potamousis KD, Apodaca J, Anantharaman TS, Lin J, Yen G, Schwartz DC, Welch RA, Blattner FR: Genome

- sequence of enterohaemorrhagic *Escherichia coli* O157:H7. *Nature* 2001, **409**:529–533.
17. Riley LW, Remis RS, Helgerson SD, McGee HB, Wells JG, Davis BR, Hebert RJ, Olcott ES, Johnson LM, Hargrett NT, Blake PA, Cohen ML: Hemorrhagic colitis associated with a rare *Escherichia coli* serotype. *N Engl J Med* 1983, **308**:681–685.
 18. Cohen MB, Giannella RA: Hemorrhagic colitis associated with *Escherichia coli* O157:H7. *Adv Intern Med* 1992, **37**:173–195.
 19. Watanabe H, Wada A, Inagaki Y, Itoh K, Tamura K: Outbreaks of enterohaemorrhagic *Escherichia coli* O157:H7 infection by two different genotype strains in Japan, 1996. *Lancet* 1996, **348**:831–832.
 20. Rivas M, Miliwebsky E, Chinen I, Roldan CD, Balbi L, Garcia B, Fiorilli G, Sosa-Estani S, Kincaid J, Rangel J, Griffin PM, Case-control Study Group: Characterization and epidemiologic subtyping of Shiga toxin-producing *Escherichia coli* strains isolated from hemolytic uremic syndrome and diarrhea cases in Argentina. *Foodborne Pathog Dis* 2006, **3**:88–96.
 21. Tzipori S, Sheoran A, Akiyoshi D, Donohue-Rolfe A, Trachtman H: Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome. *Clin Microbiol Rev* 2004, **17**:926–941.
 22. Pham TH, Gao X, Tsai K, Olsen R, Wan F, Hardwidge PR: Functional differences and interactions between the *Escherichia coli* type III secretion system effectors NleH1 and NleH2. *Infect Immun* 2012, **80**:2133–2140.
 23. Abe H, Miyahara A, Oshima T, Tashiro K, Ogura Y, Kuhara S, Ogasawara N, Hayashi T, Tobe T: Global regulation by horizontally transferred regulators establishes the pathogenicity of *Escherichia coli*. *DNA Res* 2008, **15**:25–38.
 24. Elliott SJ, Wainwright LA, McDaniel TK, Jarvis KG, Deng YK, Lai LC, McNamara BP, Donnenberg MS, Kaper JB: The complete sequence of the locus of enterocyte effacement (LEE) from enteropathogenic *Escherichia coli* E2348/69. *Mol Microbiol* 1998, **28**:1–4.
 25. Gauthier A, Puente JL, Finlay BB: Secretin of the enteropathogenic *Escherichia coli* type III secretion system requires components of the type III apparatus for assembly and localization. *Infect Immun* 2003, **71**:3310–3319.
 26. McDaniel TK, Kaper JB: A cloned pathogenicity island from enteropathogenic *Escherichia coli* confers the attaching and effacing phenotype on *E. coli* K-12. *Mol Microbiol* 1997, **23**:399–407.
 27. Tobe T, Beatson SA, Taniguchi H, Abe H, Bailey CM, Fivian A, Younis R, Matthews S, Marches O, Frankel G, Hayashi T, Pallen MJ: An extensive repertoire of type III secretion effectors in *Escherichia coli* O157 and the role of lambdoid phages in their dissemination. *Proc Natl Acad Sci U S A* 2006, **103**:14941–14946.
 28. Hartleib S, Prager R, Hedenstrom I, Lofdahl S, Tschape H: Prevalence of the new, SPI1-like, pathogenicity island ETT2 among *Escherichia coli*. *Int J Med Microbiol* 2003, **292**:487–493.
 29. Makino S, Tobe T, Asakura H, Watarai M, Ikeda T, Takeshi K, Sasakawa C: Distribution of the secondary type III secretion system locus found in enterohemorrhagic *Escherichia coli* O157:H7 isolates among Shiga toxin-producing *E. coli* strains. *J Clin Microbiol* 2003, **41**:2341–2347.
 30. Prager R, Bauerfeind R, Tietze E, Behrend J, Fruth A, Tschape H: Prevalence and deletion types of the pathogenicity island ETT2 among *Escherichia coli* strains from oedema disease and colibacillosis in pigs. *Vet Microbiol* 2004, **99**:287–294.
 31. Ren CP, Chaudhuri RR, Fivian A, Bailey CM, Antonio M, Barnes WM, Pallen MJ: The ETT2 gene cluster, encoding a second type III secretion system from *Escherichia coli*, is present in the majority of strains but has undergone widespread mutational attrition. *J Bacteriol* 2004, **186**:3547–3560.
 32. Cheng D, Zhu S, Su Z, Zuo W, Lu H: Prevalence and isoforms of the pathogenicity island ETT2 among *Escherichia coli* isolates from colibacillosis in pigs and mastitis in cows. *Curr Microbiol* 2012, **64**:43–49.
 33. Kyle JL, Cummings CA, Parker CT, Quinones B, Vatta P, Newton E, Huynh S, Swimley M, Degoricija L, Barker M, Fontanoz S, Nguyen K, Patel R, Fang R, Tebbs R, Petrauskene O, Furtado M, Mandrell RE: *Escherichia coli* serotype O55:H7 diversity supports parallel acquisition of bacteriophage at Shiga toxin phage insertion sites during evolution of the O157:H7 lineage. *J Bacteriol* 2012, **194**:1885–1896.
 34. Osawa K, Shibata M, Nishiyama Y, Kurokawa M, Yamamoto G, Kinoshita S, Kataoka N: Identification of the ETT2 locus in human diarrheagenic *Escherichia coli* by multiplex PCR. *J Infect Chemother* 2006, **12**:157–159.
 35. Miyazaki J, Ba-Thein W, Kumao T, Akaza H, Hayashi H: Identification of a type III secretion system in uropathogenic *Escherichia coli*. *FEMS Microbiol Lett* 2002, **212**:221–228.
 36. Cornelis GR: The type III secretion injectisome. *Nat Rev Microbiol* 2006, **4**:811–825.
 37. Hansen-Wester I, Hensel M: *Salmonella* pathogenicity islands encoding type III secretion systems. *Microbes Infect* 2001, **3**:549–559.
 38. Lostroh CP, Lee CA: The *Salmonella* pathogenicity island-1 type III secretion system. *Microbes Infect* 2001, **3**:1281–1291.
 39. Ehrbar K, Friebe A, Miller SI, Hardt WD: Role of the *Salmonella* pathogenicity island 1 (SPI-1) protein InvB in type III secretion of SopE and SopE2, two *Salmonella* effector proteins encoded outside of SPI-1. *J Bacteriol* 2003, **185**:6950–6967.
 40. Daefler S, Russel M: The *Salmonella typhimurium* InvB protein is an outer membrane lipoprotein required for the proper localization of InvG. *Mol Microbiol* 1998, **28**:1367–1380.
 41. Moest TP, Meresse S: *Salmonella* T3SSs: successful mission of the secret (ion) agents. *Curr Opin Microbiol* 2013, **16**:38–44.
 42. Pallen MJ: Glucoamylase-like domains in the alpha- and beta-subunits of phosphorylase kinase. *Protein Sci* 2003, **12**:1804–1807.
 43. Chaudhuri RR, Sebahia M, Hobman JL, Webber MA, Leyton DL, Goldberg MD, Cunningham AF, Scott-Tucker A, Ferguson PR, Thomas CM, Frankel G, Tang CM, Dudley EG, Roberts IS, Rasko DA, Pallen MJ, Parkhill J, Nataro JP, Thomson NR, Henderson IR: Complete genome sequence and comparative metabolic profiling of the prototypical enteroaggregative *Escherichia coli* strain 042. *PLoS One* 2010, **5**:e8801.
 44. Hardt WD, Urlaub H, Galan JE: A substrate of the centisome 63 type III protein secretion system of *Salmonella typhimurium* is encoded by a cryptic bacteriophage. *Proc Natl Acad Sci U S A* 1998, **95**:2574–2579.
 45. Norris FA, Wilson MP, Wallis TS, Galyov EE, Majerus PW: SopB, a protein required for virulence of *Salmonella dublin*, is an inositol phosphate phosphatase. *Proc Natl Acad Sci U S A* 1998, **95**:14057–14059.
 46. Zhang L, Chaudhuri RR, Constantinidou C, Hobman JL, Patel MD, Jones AC, Sarti D, Roe AJ, Vlisidou I, Shaw RK, Falciani F, Stevens MP, Gally DL, Knutton S, Frankel G, Penn CW, Pallen MJ: Regulators encoded in the *Escherichia coli* type III secretion system 2 gene cluster influence expression of genes within the locus for enterocyte effacement in enterohemorrhagic *E. coli* O157:H7. *Infect Immun* 2004, **72**:7282–7293.
 47. Ideses D, Gophna U, Paitan Y, Chaudhuri RR, Pallen MJ, Ron EZ: A degenerate type III secretion system from septicemic *Escherichia coli* contributes to pathogenesis. *J Bacteriol* 2005, **187**:8164–8171.
 48. Yao Y, Xie Y, Perace D, Zhong Y, Lu J, Tao J, Guo X, Kim KS: The type III secretion system is involved in the invasion and intracellular survival of *Escherichia coli* K1 in human brain microvascular endothelial cells. *FEMS Microbiol Lett* 2009, **300**:18–24.
 49. Sheikh J, Dudley EG, Sui B, Tamboura B, Suleman A, Nataro JP: EIIA, a HiiA-like regulator in enteroaggregative *Escherichia coli*. *Mol Microbiol* 2006, **61**:338–350.
 50. Kaper JB, Mellies JL, Nataro JP: Pathogenicity islands and other mobile genetic elements of diarrheagenic *Escherichia coli*. In *Pathogenicity islands and other mobile virulence elements*. Washington, DC: American Society for Microbiology; 1999:33–58.
 51. Prager R, Annemuller S, Tschape H: Diversity of virulence patterns among shiga toxin-producing *Escherichia coli* from human clinical cases—need for more detailed diagnostics. *Int J Med Microbiol* 2005, **295**:29–38.

doi:10.1186/1297-9716-45-32

Cite this article as: Zhou et al.: *Escherichia coli* type III secretion system 2: a new kind of T3SS? *Veterinary Research* 2014 **45**:32.